Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients (Q44311325)

1 December 2017

Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients (English)

1 reference

1 December 2017

Maryse Lapeyre-Mestre

3

1 reference

1 December 2017

Pierre Sié

4

0 references

Jean-Louis Montastruc

10

object named as

Jean-Louis Montastruc

1 reference

1 December 2017

Philippe Cestac

1

1 reference

1 December 2017

Haleh Bagheri

2

1 reference

1 December 2017

Atoussa Fouladi

5

1 reference

1 December 2017

Eric Maupas

6

1 reference

1 December 2017

Philippe Léger

7

1 reference

1 December 2017

Bernard Fontan

8

1 reference

1 December 2017

Patrice Massip

9

1 reference

1 December 2017

language of work or name

1 reference

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

26

1 reference

1 December 2017

3

1 reference

1 December 2017

197-207

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200326030-00005

1 December 2017

0 references

cites work

Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England

1 reference

12 December 2020

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

1 reference

12 December 2020

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy

1 reference

12 December 2020

Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery

1 reference

12 December 2020

[Evaluation of low molecular weight heparin prescription at the Centre Hospitalier Intercommunal de Créteil]

1 reference

12 December 2020

Can we differentiate the low-molecular-weight heparins?

1 reference

12 December 2020

[Hemorrhagic accidents with low molecular weight heparin: 15 cases]

1 reference

12 December 2020

Thrombocytosis associated with low-molecular-weight heparin

1 reference

12 December 2020

Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure

1 reference

12 December 2020

Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin

1 reference

12 December 2020

Major bleeding after hospitalization for deep-venous thrombosis.

1 reference

12 December 2020

Low-molecular-weight heparins and thrombocytosis.

1 reference

12 December 2020

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

12 December 2020

Prophylaxis of venous thromboembolism in medical patients: from medical decision tools to the use of low molecular weight heparin

1 reference

12 December 2020

Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange.

1 reference

12 December 2020

Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin

1 reference

12 December 2020

[The effect of selective serotonin-reuptake inhibitors in blood coagulation]

1 reference

12 December 2020

Thrombocytosis associated with low-molecular-weight heparin

1 reference

12 December 2020

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

1 reference

12 December 2020

[Muscle hematoma in the very elderly receiving low-molecular-weight heparins]

1 reference

12 December 2020

Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy

1 reference

12 December 2020

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

1 reference

12 December 2020

Fraxiparin, a low-molecular-weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice

1 reference

12 December 2020

Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?

1 reference

12 December 2020

[Severe hemorrhagic complications during treatment with low molecular weight heparin. Apropos of 2 cases]

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Hemorrhagic complications of anticoagulant treatment

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

12 December 2020

Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

12 December 2020

Assessing quality of life in cancer patients

1 reference

12 December 2020

Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France

1 reference

12 December 2020

Thrombocytosis after prophylactic administration of enoxaparin: unexpected findings in a Polish prospective multicenter trial on the efficacy and safety of enoxaparin in the prevention of postoperative thromboembolism

1 reference

12 December 2020

Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group

1 reference

12 December 2020

Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin.

1 reference

12 December 2020

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

12 December 2020

Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days

1 reference

12 December 2020

Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis

1 reference

12 December 2020

Low molecular weight heparin in prevention of perioperative thrombosis

1 reference

12 December 2020

Aging and heparin-related bleeding

1 reference

12 December 2020

10.2165/00002018-200326030-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

1 December 2017

0 references

1 reference